Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Merck
AstraZeneca
Mallinckrodt
Colorcon
Dow

Last Updated: May 29, 2023

MYTESI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Mytesi, and when can generic versions of Mytesi launch?

Mytesi is a drug marketed by Napo Pharms Inc and is included in one NDA. There are three patents protecting this drug.

This drug has forty-five patent family members in twenty-five countries.

The generic ingredient in MYTESI is crofelemer. One supplier is listed for this compound. Additional details are available on the crofelemer profile page.

DrugPatentWatch® Generic Entry Outlook for Mytesi

Mytesi was eligible for patent challenges on December 31, 2016.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for MYTESI
International Patents:45
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 2
Drug Prices: Drug price information for MYTESI
What excipients (inactive ingredients) are in MYTESI?MYTESI excipients list
DailyMed Link:MYTESI at DailyMed
Drug patent expirations by year for MYTESI
Drug Prices for MYTESI

See drug prices for MYTESI

Recent Clinical Trials for MYTESI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Beth Israel Deaconess Medical CenterPhase 4
Napo Pharmaceuticals, Inc.Phase 4

See all MYTESI clinical trials

Pharmacology for MYTESI
Drug ClassAntidiarrheal

US Patents and Regulatory Information for MYTESI

MYTESI is protected by three US patents.

Patents protecting MYTESI

Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA

Methods and compositions for treating HIV-associated diarrhea
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA

Methods and compositions for treating HIV-associated diarrhea
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MYTESI

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 ⤷  Try a Trial ⤷  Try a Trial
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 ⤷  Try a Trial ⤷  Try a Trial
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for MYTESI

See the table below for patents covering MYTESI around the world.

Country Patent Number Title Estimated Expiration
Spain 2326933 ⤷  Try a Trial
Peru 20140036 METODOS Y COMPOSICIONES PARA TRATAR DIARREA ASOCIADA CON VIH ⤷  Try a Trial
South Africa 201303136 METHODS AND COMPOSITION FOR TREATING HIV-ASSOCIATED DIARRHEA ⤷  Try a Trial
Australia 4988197 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Mallinckrodt
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.